Abiomed (NASDAQ: ABMD), the first company to implant a totally artificial heart in a patient back in 2001, develops technology to help hearts recover. The company's main products are the world's smallest heart pump, the Impella, and its supporting SmartAssist technology.
Abiomed's share price vaulted up 31.8% in April, according to data provided by S&P Global Market Intelligence; most of it came at the end of the month, after the company posted heartening results for the fiscal fourth quarter of 2020. There were concerns that results would be negatively affected due to COVID-19 disruptions to non-lifesaving procedures.
For fiscal year 2020, Abiomed reported total revenue of $840.9 million, up 9% year over year compared to 2019 revenue of $769.4 million. Operating income was $249.2 million, up 10.9% year over year, compared to 2019 operating income of $224.8 million.